Company profile
Valeo Pharma Inc.
OTC: VPHIF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Kirkland, QCReports USD
#467 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ —GM —SS 33
v0.1 · 5/100 weight · pillars only
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ market scale, balance-sheet leverage
Methodology →Revenue TTM
$39.3M
Rev growth YoY (TTM)
-1.4%
Net income (FY)
-$20.6M
Employees
70
as of 2026-08-29
Market cap
$9.9k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$40.0M53.9M CAD2023
Net income-$20.6M-27.8M CAD2023
Operating income-$12.8M-17.2M CAD2023
Total assets$29.7M41.2M CAD2023
Liabilities$58.8M81.5M CAD2023
Equity-$29.1M-40.3M CAD2023
Revenue trend
FY2017 – FY2023 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Valeo Pharma Inc.’s revenue?
Valeo Pharma Inc. booked $40.0M in FY2023 revenue, growing 85% year over year — faster than most Healthcare companies we track, at a -51.6% net margin.
Peers · Healthcare
Editas Medicine, Inc.45DAlpha Teknova, Inc.58CVoyager Therapeutics, Inc.53DEnveric Biosciences, Inc.31DBig Tree Group, Inc.——Kymera Therapeutics, Inc.53DKey facts
CEOKyle Steiger
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersKirkland, QC
ExchangeOTC: VPHIF
Employees70
IPO date2020-09-23
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.